astrazeneca_sign_sky

AstraZeneca’s Qtrilment scores European authorisation in type 2 diabetes

pharmafile | November 15, 2019 | News story | Medical Communications, Sales and Marketing |  AstraZeneca, EU, Europe, Qtrilmet, diabetes, pharma, type 2 diabetes 

Qtrilmet (metformin hydrochloride, saxagliptin and dapagliflozin) has secured approval in Europe, its manufacturer AstraZeneca has revealed, as a therapy to improve glycaemic control in adults with type-2 diabetes (T2D).

Specifically, the approval covers T2D patients who have not experienced adequate glycaemic control with metformin with or without sulphonylurea and in combination with either Onglyza or Forxiga, or in patients who are already receiving treatment with metformin, Onglyza and Forxiga.

Data from five Phase 3 trials supporting the application demonstrated that the combination of Forxiga (dapagliflozin) and Onglyza (saxagliptin), when used alongside metformin in patients with inadequately controlled type 2 diabetes, proved superior in reducing blood glucose levels compared to metformin paired with either Forxiga, Onglyza, or glimepiride.

This superior combo, with or without glimepiride, also proved itself non-inferior to the combination of insulin and metformin with or without glimepiride in blood glucose level reduction.

Advertisement

The European decision follows the drug’s US approval in March this year.

Matt Fellows

Related Content

Sharp invests $100m in US and EU manufacturing and packaging facilities

Sharp Services, a pharmaceutical packaging and sterile manufacturing specialist, has announced investments totalling $100m across …

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Astra Zeneca Logo

NICE recommends Benralizumab for Rare Form of Vasculitis

The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …

The Gateway to Local Adoption Series

Latest content